SVA Sinovac Biotech Ltd

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13D

 

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

 

 

SINOVAC BIOTECH LTD.

(Name of issuer)

 

 

Common Shares

(Title of class of securities)

 

P8696W104

(CUSIP number)

 

No. 39 Shangdi Xi Road

Haidian District, Beijing 100085

People’s Republic of China

+86-10-8289-0088

 

With a copy to:

 

David T. Zhang

Kirkland & Ellis

26th Floor, Gloucester Tower

The Landmark

15 Queen’s Road, Central

Hong Kong

 

(Name, address and telephone number of person authorized to receive notices and communications)

 

January 30, 2016

(Date of event which requires filing of this statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

 

 

*  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

 

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

CUSIP No. P8696W104

SCHEDULE 13D

Page 2 of 5 Pages

 

1	Names of Reporting Persons
	Weidong Yin
2	Check the Appropriate Box if a Member of a Group	(a) ¨
		(b) x
3	SEC Use Only
4	Source of Funds PF
5	Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e)	¨
6	Citizenship or Place of Organization
	People’s Republic of China

Number of Shares Beneficially Owned by Each Reporting Person With	7	Sole Voting Power
		6,049,500
	8	Shared Voting Power
		0
	9	Sole Dispositive Power
		6,049,500
	10	Shared Dispositive Power
		0

11	Aggregate Amount Beneficially Owned by Each Reporting Person
	6,049,500
12	Check if the Aggregate Amount In Row (11) Excludes Certain Shares	¨
13	Percent of Class Represented By Amount In Row (11)
	10.6%(1)
14	Type of Reporting Person
	IN

⁽¹⁾ Based on 56,907,761 shares of Common Shares issued and outstanding as of December 31, 2015.

 

 

CUSIP No. P8696W104

SCHEDULE 13D

Page 3 of 5 Pages

 

This Amendment No. 1 to Schedule 13D is being filed on behalf of Weidong Yin to amend the Schedule 13D filed on February 7, 2008 (the “Original Schedule 13D”). The information in each Item below amends the information disclosed under the corresponding Item of the Original Schedule 13D. Except as amended and supplemented herein, the information set forth in the Original Schedule 13D remains unchanged. Capitalized terms used herein have meanings as assigned thereto in the Original Schedule 13D unless defined herein. The information set forth in response to each separate Item below shall be deemed to be a response to all Items where such information is relevant.

 

Item 1. Security and Issuer

 

The last sentence of Item 1 of the Original Schedule 13D is hereby amended and restated as follows:

 

The principal executive offices of the Issuer are located at No. 39, Shangdi Xi Road, Haidian District, Beijing 100085, the People’s Republic of China. The Issuer’s telephone number at this address is +86-10-8289-0088.

 

Item 4. Purpose of Transaction

 

Item 4 of the Original 13D is hereby amended by adding the following paragraphs to the end thereof:

 

On January 30, 2016, Weidong Yin and SAIF Partners IV L.P. (together with Weidong Yin, collectively, the “Buyer Group”) submitted a preliminary non-binding proposal letter (the “Proposal Letter”) to the Issuer’s board of directors, a copy of which is attached hereto as Exhibit 7.01.

 

In the Proposal Letter, the Buyer Group proposed to acquire, through an acquisition vehicle to be formed by the Buyer Group, all of the outstanding Common Shares that are not already directly or indirectly beneficially owned by the Buyer Group for cash consideration equal to US$6.18 per Common Share (the “Acquisition”). The Acquisition will be funded by a combination of debt and equity capital. Equity financing will be provided by the Buyer Group in the form of cash and rollover equity in the Company. Debt financing is expected to be provided by loans from third party financial institutions.

 

The Buyer Group also stated in the Proposal Letter that that they are currently interested only in pursuing the Acquisition and are not interested in selling their shares in any other transaction involving the Issuer. The Buyer Group expects to complete customary due diligence for the Acquisition in a timely manner and in parallel with discussions on definitive agreements.

 

This Proposal Letter constitutes only a preliminary indication of interest by the Buyer Group and does not contain all matters upon which agreement must be reached in order to consummate the proposed Acquisition, nor does it create any binding rights or obligations in favor of any person. The parties will be bound only upon the execution of mutually agreeable definitive documentation. If the Acquisition is completed, Common Shares would be delisted from the NASDAQ Global Select Market, and the Issuer’s reporting obligations under the Act would terminate.

 

The descriptions of the Proposal Letter set forth above in this Item 4 do not purport to be complete and are qualified in their entirety by reference to the full text of the Proposal Letter which has been filed as Exhibit 7.01 and is incorporated herein by this reference.

 

None of the Issuer or the Buyer Group is obligated to complete the transactions described herein, and a binding commitment with respect to the Acquisition will result only from the execution of definitive documents, and then will be on the terms provided in such documentation.

 

Except as indicated above, the Buyer Group currently does not have any plans or proposals that relate to or would result in any matters listed in Items 4(a)-(j) of Schedule 13D. Consummation of the Acquisition could result in one or more of the actions specified in Items 4(a)-(j) of Schedule 13D, including the acquisition or disposition of securities of the Issuer, a merger or other extraordinary transaction involving the Issuer, a change to the board of directors of the Issuer to consist solely of persons to be designated by the acquisition vehicle to be formed by the Buyer Group, and a change in the Issuer’s articles of incorporation and by-laws to reflect that the Issuer would become a privately held company. In addition, the Buyer Group reserve their right to change his plans and intentions in connection with any of the actions discussed in this item 4, including, among others, the purchase price and the financing arrangement for the transactions contemplated under the Proposal Letter (including the Acquisition). Any action taken by the Buyer Group may be effected at any time and from time to time, subject to any applicable limitations imposed by any applicable laws. No assurance can be given that any proposal, any definitive agreement or any transaction relating to the Acquisition will be entered into or be consummated.

 

 

CUSIP No. P8696W104

SCHEDULE 13D

Page 4 of 5 Pages

 

Item 5. Interest in Securities of the Issuer

 

Item 5 of the Original Schedule 13D is hereby amended and restated as follows:

 

(a) Weidong Yin currently owns 6,049,500 shares of Common Shares, which represents approximately 10.6% of the total Common Shares issued and outstanding as of December 31, 2015.

 

(b) Weidong Yin has the sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of 6,049,500 shares of Common Shares directly owned by him.

 

(c) Except as otherwise described herein, and to the knowledge of Weidong Yin, Weidong Yin has not affected any transaction in the Common Shares during the past sixty (60) days.

 

(d) Except as otherwise described herein, and to the knowledge of Weidong Yin, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Shares owned by Weidong Yin.

 

(e) Not applicable.

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to the Securities of the Issuer

 

Item 6 of the Original Schedule 13D is hereby amended and restated as follows:

 

The Proposal Letter, which has been filed as Exhibit 7.01 to this statement, is incorporated herein by reference in its entirety. In addition, the information set forth in Items 3, 4 and 5 of this statement is incorporated by reference in its entirety into this Item 6. Except as otherwise described herein, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between Weidong Yin and any other person with respect to the voting or disposition of the shares of Common Shares beneficially owned by Weidong Yin.

 

Item 7. Material to be Filed as Exhibits

 

Item 7 of the Original Schedule 13D is hereby amended and restated as follows:

 

Exhibit 7.01: Proposal Letter from Mr. Weidong Yin and SAIF Partners IV L.P. to the board of directors of the Issuer, dated as of January 30, 2016.

 

 

CUSIP No. P8696W104

SCHEDULE 13D

Page 5 of 5 Pages

 

Signature

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 5, 2016
	/s/ Weidong Yin
	Weidong Yin

 

 

Exhibit 7.01

 

January 30, 2016

 

The Board of Directors

Sinovac Biotech Ltd.

No. 39 Shangdi Xi Road,

Haidian District, Beijing 100085

People’s Republic of China

 

 

Dear Members of the Board of Directors,

 

The undersigned, Mr. Weidong Yin (“Mr. Yin”), chairman, president and chief executive officer of Sinovac Biotech Ltd. (the “Company”) and SAIF Partners IV L.P. (together with Mr. Yin, collectively, the “Buyer Group”) is pleased to submit this preliminary non-binding proposal (the “Proposal”) to acquire all of the outstanding common shares of the Company that are not already owned by the Buyer Group on the principal terms and conditions described in this letter (the “Transaction”).

 

We believe that our Proposal provides a very attractive opportunity to the Company’s shareholders. Our Proposal represents a premium of approximately 23.11% to the closing price of the Company’s common shares on January 29, 2016, and a premium of approximately 16.62% to the volume-weighted average closing price of the Company’s common shares during the last 90 trading days.

 

Set forth below are the key terms of our Proposal.

 

1. Consortium. We will form an acquisition vehicle for the purpose of implementing the Transaction. Please also note that the Buyer Group is currently interested only in pursuing the Transaction and are not interested in selling their shares in any other transaction involving the Company.

 

2. Transaction and Purchase Price. We propose to acquire all of the outstanding common shares of the Company not already owned by us at a purchase price equal to US$6.18 per common share in cash through an acquisition vehicle newly formed by the Buyer Group with and into the Company.

 

3. Financing. We intend to finance the Transaction with a combination of debt and equity capital. Equity financing will be provided by the Buyer Group in the form of cash and rollover equity in the Company. Debt financing is expected to be provided by loans from third party financial institutions. We are confident that we can timely secure adequate financing to consummate the Transaction.

 

4. Due Diligence. We believe that we will be in a position to complete customary due diligence for the Transaction in a timely manner and in parallel with discussions on definitive agreements.

 

5. Definitive Agreements. We have engaged Kirkland & Ellis International LLP as our international legal counsel and are prepared to promptly provide and negotiate definitive agreements for the Transaction (the “Definitive Agreements”). The Definitive Agreements will provide for representations, warranties, covenants and conditions which are typical, customary and appropriate for transactions of this type.

 

 

6. Process. We believe that the Transaction will provide superior value to the Company’s public shareholders. We recognize of course that the board of directors of the Company will evaluate the Transaction independently before it can make its determination whether to endorse it. Given our involvement in the Transaction, we would expect that the independent members of the board of directors will proceed to consider our Proposal and the Transaction.

 

7. Confidentiality. The Buyer Group will, as required by law, promptly file a Schedule 13D with the Securities and Exchange Commission to disclose this letter. We are sure you will agree, however, that it is in all of our interests to ensure that we otherwise proceed in a strictly confidential manner, unless otherwise required by law, until we have executed definitive agreements or terminated our discussions.

 

8. No Binding Commitment. This Proposal is not a binding offer, agreement or agreement to make a binding offer or agreement at any point in the future. This letter is a preliminary indication of interest by the Buyer Group and does not contain all matters upon which agreement must be reached in order to consummate the proposed Transaction, nor does it create any binding rights or obligations in favor of any person. The parties will be bound only upon the execution of mutually agreeable definitive documentation.

 

9. Governing Law. This letter shall be governed by, and construed in accordance with, the internal laws of the State of New York.

 

* * * * *

 

 

In closing, we would like to express our commitment to working together to bring this Transaction to a successful and timely conclusion. Should you have any questions regarding this Proposal, please do not hesitate to contact us. We look forward to hearing from you.

 

 

Sincerely,

 

 

/s/ Weidong Yin

Weidong Yin

 

  

SAIF Partners IV L.P. 

By SAIF Partners IV L.P., its general partner 

By SAIF IV GP Capital Ltd., its general partner

 

 

/s/ Andrew Y. Yan

Name: Andrew Y. Yan

Title: Director